Spots Global Cancer Trial Database for Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Official Title: An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Abexinostat as Monotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Study ID: NCT03936153
Conditions
Interventions
Study Description
Brief Summary: An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Detailed Description: An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, , China
China-Japan Friendship Hospital, Beijing, , China
Peking University Third Hospital, Beijing, , China
West China Hospital, Sichuan University, Chengdu, , China
The First Affiliate Hospital of Dalian Medical University, Dalian, , China
Fujian Medical University Union Hospital, Fuzhou, , China
Fujian Provincial Cancer Hospital, Fuzhou, , China
Cancer Center of Guangzhou Medical University, Guangzhou, , China
Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University, Guangzhou, , China
Zhejiang Cancer Hospital, Hangzhou, , China
The Affiliated Tumor Hospital of Harbin Medical University, Harbin, , China
The First Hospital of Lanzhou University, Lanzhou, , China
Linyi Cancer Hospital, Linyi, , China
Nantong Tumor Hospital, Nantong, , China
Shanghai Jiao Tong University School Medicine, Shanghai, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Second People's Hospital of Shenzhen, Shenzhen, , China
The Forth Hospital of Hebei Medical University, Shijiazhuang, , China
First Hospital of Shanxi Medical University, Taiyuan, , China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, , China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, , China
Henan Cancer Hospital, Zhengzhou, , China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, , China
Contact Details
Name: Yuankai SHI, Prof
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
